在心力衰竭中,基于设备的疗法以表型为导向的方法
Phuuwadith Wattanachayakul1,2, Veraprapas Kittipibul3,4, William T Abraham5
1Department of Medicine, Jefferson Einstein Hospital, Philadelphia, PA, USA.
Heart failure reviews
|October 1, 2025
概括
设备疗法可以改善心力衰竭 (HF) 管理. 本综述提出了一种表型驱动的框架,以优化心力衰竭患者的设备选择,增强治疗效益.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
背景情况:
- 基于设备的疗法对于心力衰竭 (HF) 管理至关重要,它提供了超出药物治疗的好处.
- 目前的设备选择缺乏量身定制的框架,导致有效疗法在符合条件的患者中未得到充分利用.
- 解决这个差距可以最大限度地为多样化的HF群体带来治疗效益.
研究的目的:
- 根据临床试验证据,审查基于设备的高频疗法的当前作用.
- 提出一种表型驱动的框架,用于指导HF患者的器械选择.
- 通过设备治疗确定改善HF护理的未来方向.
主要方法:
- 对基于设备的高频率治疗的临床试验的文献综述.
- 开发一种以表型为驱动的设备选择框架.
- 分析HF患者的个人资料,包括减少和保留的喷射分数.
主要成果:
- 设备疗法在治疗心力衰竭方面发挥着不可或缺的作用.
- 提出了一个全面的,以表型为导向的设备选择框架.
- 该框架旨在指导临床医生为个体HF患者选择最佳设备.
结论:
- 对设备选择的结构化方法可以增强心力衰竭管理.
- 拟议的框架解决了对高频器件个性化治疗的需求.
- 未来的研究应该专注于改进设备策略,以改善患者的治疗结果.
相关概念视频
Heart Failure VI: Adjunct Therapies
261
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
261
Cardiomyopathy V: Interprofessional Care
338
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
338
Cardiomyopathy II: Dilated Cardiomyopathy
470
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
470
Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
Pathophysiology of Heart Failure
2.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.9K
Cardiomyopathy III: Hypertrophic Cardiomyopathy
411
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
411


